Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer

Biomaterials

Volumn 34, Issue 35, 2013, Pages 8909-8917

  Parekh, Parag ^a,b   Kamble, Sanchit ^a,b   Zhao, Nianxi ^a,b   Zeng, Zihua ^a,b   Portier, Bryce P ^a   Zu, Youli ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

ALCL; Cancer immunotherapy; CD30; CHL; Lymphoma; SsDNA aptamer

Indexed keywords

ALCL; CANCER IMMUNOTHERAPY; CD30; CHL; LYMPHOMA; SSDNA APTAMER;

CELL DEATH; CELL SIGNALING; DISEASES;

ONCOLOGY;

APTAMER; CD30 ANTIGEN; SINGLE STRANDED DNA;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER THERAPY; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL;

ALCL; CANCER IMMUNOTHERAPY; CD30; CHL; LYMPHOMA; SSDNA APTAMER;

ANTIGENS, CD30; APOPTOSIS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL LINE, TUMOR; HL-60 CELLS; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; K562 CELLS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84883215679     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.099     Document Type: Article

References (55)

1. Famulok M., Mayer G., Blind M. Nucleic acid aptamers from selection invitro to applications invivo. Acc Chem Res 2000, 33:591-599.
2. Gold L., Brody E., Heilig J., Singer B. One, two, infinity: genomes filled with aptamers. Chem Biol 2002, 9:1259-1264.
3. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999, 45:1628-1650.
4. Horie R., Watanabe T. CD30: expression and function in health and disease. Semin Immunol 1998, 10:457-470.
5. Chiarle R., Podda A., Prolla G., Gong J., Thorbecke G.J., Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 1999, 90:157-164.
6. Nawrocki J.F., Kirsten E.S., Fisher R.I. Biochemical and structural properties of a Hodgkin's disease-related membrane protein. JImmunol 1988, 141:672-680.
7. Stein H., Mason D., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985, 66:848-858.
8. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2008, 9:15-27.
9. Stein H., Foss H.D., Dürkop H., Marafioti T., Delsol G., Pulford K., et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000, 96:3681-3695.
10. Sotlar K., Cerny-Reiterer S., Petat-Dutter K., Hessel H., Berezowska S., Müllauer L., et al. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2010, 24:585-595.
11. Medeiros L.J., Elenitoba-Johnson K.S.J. Anaplastic large cell lymphoma. Am J Clin Pathol 2007, 127:707-722.
12. Vaklavas C., Forero-Torres A. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol 2012.
13. Younes A., Bartlett N.L., Leonard J.P., Kennedy D.A., Lynch C.M., Sievers E.L., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. NEngl J Med 2010, 363:1812-1821.
14. Fanale M.A., Forero-Torres A., Rosenblatt J.D., Advani R.H., Franklin A.R., Kennedy D.A., et al. Aphase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012, 18:248-255.
15. Kennedy M.K., Willis C.R., Armitage R.J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006, 118:143-152.
16. Del Prete G., De Carli M., Almerigogna F., Daniel C., D'elios M., Zancuoghi G., et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995, 9:81-86.
17. Zhang P., Zhao N., Zeng Z., Feng Y., Tung C.H., Chang C.C., et al. Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells. Lab Invest 2009, 89:1423-1432.
18. Zeng Z., Zhang P., Zhao N., Sheehan A.M., Tung C.H., Chang C.C., et al. Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues. Mod Pathol 2010, 23:1553-1558.
19. Keefe A.D., Cload S.T. SELEX with modified nucleotides. Curr Opin Chem Biol 2008, 12:448-456.
20. Bell N.M., Micklefield J. Chemical modification of oligonucleotides for therapeutic, bioanalytical and other applications. Chembiochem 2009, 10:2691-2703.
21. Micklefield J. Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr Med Chem 2001, 8:1157-1179.
22. Katoh K., Standley D.M. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 2013, 30:772-780.
23. Katoh K., Misawa K., Kuma Ki, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 2002, 30:3059-3066.
24. Zuker M., Mathews D.H., Turner D.H. Algorithms and thermodynamics for RNA secondary structure prediction: a practical guide. RNA biochemistry and biotechnology 1999, 11-43. Springer.
25. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003, 31:3406-3415.
26. Zuker M. Calculating nucleic acid secondary structure. Curr Opin Struct Biol 2000, 10:303-310.
27. Podack E.R., Strbo N., Sotosec V., Muta H. CD30-governor of memory T cells?. Ann NY Acad Sci 2002, 975:101-113.
28. Schneider C., Hübinger G. Pleiotropic signal transduction mediated by human CD30: a member of the tumor necrosis factor receptor (TNFR) family. Leuk Lymphoma 2002, 43:1355-1366.
29. Schnell R., Dietlein M., Staak J.O., Borchmann P., Schomaecker K., Fischer T., et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. JClin Oncol 2005, 23:4669-4678.
30. Fang X., Tan W. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 2010, 43:48-57.
31. Campbell M.A., Wengel J. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Chem Soc Rev 2011, 40:5680-5689.
32. Joachimi A., Benz A., Hartig J.S. Acomparison of DNA and RNA quadruplex structures and stabilities. Bioorg Med Chem 2009, 17:6811-6815.
33. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
34. Ellington A.D., Szostak J.W. Invitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
35. Mallikaratchy P., Stahelin R.V., Cao Z., Cho W., Tan W. Selection of DNA ligands for protein kinase C-δ. Chem Commun 2006, 3229-3231.
36. Martin J.A., Parekh P., Kim Y., Morey T.E., Sefah K., Gravenstein N., et al. Selection of an aptamer antidote to the anticoagulant drug bivalirudin. PloS One 2013, 8:e57341.
37. Javaherian S., Musheev M.U., Kanoatov M., Berezovski M.V., Krylov S.N. Selection of aptamers for a protein target in cell lysate and their application to protein purification. Nucleic Acids Res 2009, 37. e62.
38. Gopinath S.C.B. Methods developed for SELEX. Anal Bioanal Chem 2007, 387:171-182.
39. Shangguan D., Li Y., Tang Z., Cao Z.C., Chen H.W., Mallikaratchy P., et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006, 103:11838-11843.
40. Daniels D.A., Chen H., Hicke B.J., Swiderek K.M., Gold L. Atenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 2003, 100:15416-15421.
41. Bayrac A.T., Sefah K., Parekh P., Bayrac C., Gulbakan B., Oktem H.A., et al. Invitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci 2011, 2:175-181.
42. Parekh P., Tang Z., Turner P.C., Moyer R.W., Tan W. Aptamers recognize glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells. Anal Chem 2010, 82:8642.
43. Sefah K., Tang Z., Shangguan D., Chen H., Lopez-Colon D., Li Y., et al. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 2009, 23:235-244.
44. Li N., Ebright J.N., Stovall G.M., Chen X., Nguyen H.H., Singh A., et al. Technical and biological issues relevant to cell typing with aptamers. JProteome Res 2009, 8:2438-2448.
45. Gold L., Ayers D., Bertino J., Bock C., Bock A., Brody E.N., et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS One 2010, 5:e15004.
46. Sefah K., Shangguan D., Xiong X., O'Donoghue M.B., Tan W. Development of DNA aptamers using cell-SELEX. Nat Protoc 2010, 5:1169-1185.
47. Aizawa S., Nakano H., Ishida T., Horie R., Nagai M., Ito K., et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF 2 are involved in CD30-mediated NFκB activation. JBiol Chem 1997, 272:2042-2045.
48. Arch R.H., Gedrich R.W., Thompson C.B. Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death. Genes Dev 1998, 12:2821-2830.
49. Hirsch B., Hummel M., Bentink S., Fouladi F., Spang R., Zollinger R., et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am J Pathol 2008, 172:510-520.
50. Mir S.S., Richter B.W.M., Duckett C.S. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000, 96:4307-4312.
51. Famulok M., Mayer G. Aptamers as tools in molecular biology and immunology. Curr Top Microbiol Immunol 1999, 243:123-136.
52. Hicke B.J., Watson S.R., Koenig A., Lynott C.K., Bargatze R.F., Chang Y.-F., et al. DNA aptamers block L-selectin function invivo. Inhibition of human lymphocyte trafficking in SCID mice. JClin Invest 1996, 98:2688.
53. Zhou J., Li H., Li S., Zaia J., Rossi J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008, 16:1481-1489.
54. McNamara J.O., Kolonias D., Pastor F., Mittler R.S., Chen L., Giangrande P.H., et al. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. JClin Invest 2008, 118:376.
55. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165) inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. JBiol Chem 1998, 273:20556-20567.